Table 3 T2 signal changes in RT-induced MCT studies using MRI (No decrease or dose-dependency were reported)

Van Der Velde et al., [50]

80

HL & NHL

-

No differences were noted between

cancer patients and healthy control at 20 years post-RT

(50±3 ms vs 50±2 ms, p=0.13)

Speers et al., [47]

51

Breast

-

No significant changes of T2 signal

over different time points (therapy completion and 3 months post-RT)

Vallabhaneni et al., [54]

11

Lung, breast, lymphoma

-

No significant %T2 changes in patients with higher radiation (3.9±9.5%) or patients with minimal radiation (-3.4±12.1%) at 6-months following RT

Tahir et al., [55]

66

Breast

In epirubicin-chemotherapy-based

followed by RT group: increased at therapy completion compared to baseline

(48±3 ms vs 45±3 ms, P<0.001)

In epirubicin-chemotherapy-based

followed by RT group: returned to baseline at

13±2 months (46±3 ms)

-

In left-sided RT only group: constant at baseline (46±3 ms),

therapy completion (47±2 ms) and

after 13±2 months (46±3 ms)